In yesterday’s Wall Street session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares traded at $8.12, down -0.49% from the previous session.
14 analysts cover Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $8.00, we find $10.50. Given the previous closing price of $8.16, this indicates a potential upside of 28.68 percent. TEVA stock price is now -15.97% away from the 50-day moving average and -10.73% away from the 200-day moving average. The market capitalization of the company currently stands at $9.10B.
The stock has received a hold rating from 7 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $10.75 as their price target over the next twelve months.
With the price target enhanced from $7 to $8, UBS Upgraded its rating from Sell to Neutral for Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA).
In other news, Kalif Eliyahu Sharon, EVP, Chief Financial Officer sold 35,125 shares of the company’s stock on Aug 07. The stock was sold for $341,889 at an average price of $9.73. Upon completion of the transaction, the EVP, Chief Financial Officer now directly owns 99,162 shares in the company, valued at $0.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, Chief Accounting Officer Weiss Amir sold 1,981 shares of the business’s stock. A total of $19,658 was realized by selling the stock at an average price of $9.92. This leaves the insider owning 42,442 shares of the company worth $0.34 million. Insiders disposed of 77,421 shares of company stock worth roughly $0.63 million over the past 1 year. A total of 0.01% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TEVA stock. A new stake in Teva- Pharmaceutical Industries Ltd. ADR shares was purchased by SLATE PATH CAPITAL LP during the first quarter worth $100,988,000. SOLEUS CAPITAL MANAGEMENT, L.P. invested $34,510,000 in shares of TEVA during the first quarter. In the first quarter, ASSENAGON ASSET MANAGEMENT S.A. acquired a new stake in Teva- Pharmaceutical Industries Ltd. ADR valued at approximately $14,943,000. AFFINITY ASSET ADVISORS, LLC acquired a new stake in TEVA for approximately $12,992,000. ROKOS CAPITAL MANAGEMENT LLP purchased a new stake in TEVA valued at around $11,003,000 in the second quarter. In total, there are 608 active investors with 44.06% ownership of the company’s stock.
On Friday morning Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) stock kicked off with the opening price of $8.13. During the past 12 months, Teva- Pharmaceutical Industries Ltd. ADR has had a low of $7.09 and a high of $11.44. As of last week, the company has a debt-to-equity ratio of 2.98, a current ratio of 1.02, and a quick ratio of 0.67. The fifty day moving average price for TEVA is $9.63 and a two-hundred day moving average price translates $9.09 for the stock.
The latest earnings results from Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.56, beating analysts’ expectations of $0.52 by 0.04. This compares to -$0.23 EPS in the same period last year. The net profit margin was -14.85% and return on equity was -27.76% for TEVA. The company reported revenue of $3.88 billion for the quarter, compared to $3.79 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.43 percent. For the current quarter, analysts expect TEVA to generate $3.72B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/12/2017. Investors who held shares on 11/28/2017 were paid a $0.085 dividend.
Teva- Pharmaceutical Industries Ltd. ADR(TEVA) Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company’s products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn’s disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
